These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 37444515)

  • 21. Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab.
    Baumann N; Arndt C; Petersen J; Lustig M; Rösner T; Klausz K; Kellner C; Bultmann M; Bastian L; Vogiatzi F; Leusen JHW; Burger R; Schewe DM; Peipp M; Valerius T
    Front Immunol; 2022; 13():949140. PubMed ID: 36052078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD47-SIRPα Controls ADCC Killing of Primary T Cells by PMN Through a Combination of Trogocytosis and NADPH Oxidase Activation.
    Gondois-Rey F; Miller T; Laletin V; Morelli X; Collette Y; Nunès J; Olive D
    Front Immunol; 2022; 13():899068. PubMed ID: 35795660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2.
    Wieboldt R; Sandholzer M; Carlini E; Lin CW; Börsch A; Zingg A; Lardinois D; Herzig P; Don L; Zippelius A; Läubli H; Mantuano NR
    Cell Mol Immunol; 2024 May; 21(5):495-509. PubMed ID: 38448555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients.
    Benmerzoug S; Chevalier MF; Verardo M; Nguyen S; Cesson V; Schneider AK; Dartiguenave F; Rodrigues-Dias SC; Lucca I; Jichlinski P; Roth B; Nardelli-Haefliger D; Derré L
    Eur Urol Focus; 2022 May; 8(3):748-751. PubMed ID: 34147404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kindlin3-Dependent CD11b/CD18-Integrin Activation Is Required for Potentiation of Neutrophil Cytotoxicity by CD47-SIRPα Checkpoint Disruption.
    Bouti P; Zhao XW; Verkuijlen PJJH; Tool ATJ; van Houdt M; Köker N; Köker MY; Keskin O; Akbayram S; van Bruggen R; Kuijpers TW; Matlung HL; van den Berg TK
    Cancer Immunol Res; 2021 Feb; 9(2):147-155. PubMed ID: 33355195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Siglec Receptors Modulate Dendritic Cell Activation and Antigen Presentation to T Cells in Cancer.
    Wang J; Manni M; Bärenwaldt A; Wieboldt R; Kirchhammer N; Ivanek R; Stanczak M; Zippelius A; König D; Rodrigues Manutano N; Läubli H
    Front Cell Dev Biol; 2022; 10():828916. PubMed ID: 35309936
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy.
    Shen W; Shi P; Dong Q; Zhou X; Chen C; Sui X; Tian W; Zhu X; Wang X; Jin S; Wu Y; Chen G; Qiu L; Zhai W; Gao Y
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy.
    Feng H; Feng J; Han X; Ying Y; Lou W; Liu L; Zhang L
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
    Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
    J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
    Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
    Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.
    Adams OJ; Stanczak MA; von Gunten S; Läubli H
    Glycobiology; 2018 Sep; 28(9):640-647. PubMed ID: 29309569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sialylated IgG in epithelial cancers inhibits antitumor function of T cells via Siglec-7.
    Fan T; Liao Q; Zhao Y; Dai H; Song S; He T; Wang Z; Huang J; Zeng Z; Guo H; Zhang H; Qiu X
    Cancer Sci; 2023 Feb; 114(2):370-383. PubMed ID: 36310398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα "don't eat me" immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation.
    Hendriks MAJM; Ploeg EM; Koopmans I; Britsch I; Ke X; Samplonius DF; Helfrich W
    Oncoimmunology; 2020 Sep; 9(1):1824323. PubMed ID: 33299654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting glycosylated antigens on cancer cells using siglec-7/9-based CAR T-cells.
    Meril S; Harush O; Reboh Y; Matikhina T; Barliya T; Cohen CJ
    Mol Carcinog; 2020 Jul; 59(7):713-723. PubMed ID: 32391973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sialylation acts as a checkpoint for innate immune responses in the central nervous system.
    Klaus C; Liao H; Allendorf DH; Brown GC; Neumann H
    Glia; 2021 Jul; 69(7):1619-1636. PubMed ID: 33340149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy.
    Yu Y; Peng W
    Cancer Biol Med; 2023 May; 20(5):369-84. PubMed ID: 37133224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell-mediated tumor responses.
    Daly J; Sarkar S; Natoni A; Stark JC; Riley NM; Bertozzi CR; Carlsten M; O'Dwyer ME
    Blood Adv; 2022 Jun; 6(11):3352-3366. PubMed ID: 35294519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting myeloid checkpoint Siglec-10 reactivates antitumor immunity and improves anti-programmed cell death 1 efficacy in gastric cancer.
    Lv K; Sun M; Fang H; Wang J; Lin C; Liu H; Zhang H; Li H; He H; Gu Y; Li R; Shao F; Xu J
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37935567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic variation of human neutrophil Fcγ receptors and SIRPα in antibody-dependent cellular cytotoxicity towards cancer cells.
    Treffers LW; Zhao XW; van der Heijden J; Nagelkerke SQ; van Rees DJ; Gonzalez P; Geissler J; Verkuijlen P; van Houdt M; de Boer M; Kuijpers TW; van den Berg TK; Matlung HL
    Eur J Immunol; 2018 Feb; 48(2):344-354. PubMed ID: 28952147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.